Ask about this productRelated genes to: MAGEA4 Blocking Peptide
- Gene:
- MAGEA4 NIH gene
- Name:
- MAGE family member A4
- Previous symbol:
- MAGE4
- Synonyms:
- MAGE4A, MAGE4B, MAGE-41, MAGE-X2, MGC21336, CT1.4
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 1994-04-04
- Date modifiied:
- 2015-11-13
Related products to: MAGEA4 Blocking Peptide
Related articles to: MAGEA4 Blocking Peptide
- The aggressive cancer known as Esophageal Squamous Cell Carcinoma (ESCC) has a dismal prognosis. Epigenetic changes such as demethylation have a significant impact on ESCC development and progression. - Source: PubMed
Publication date: 2026/06/08
Sheng YiMa JieLi YangYin ZihuanGao XukunLuo RuixingSheng BoxiangZhu XueyingZhang Renquan - T cell receptor-engineered T cell (TCR-T) therapy represents an innovative tumor immunotherapy. Distinct from CAR-T, it recognizes MHC-restricted antigens to target tumor-specific antigens, exhibiting unique advantages for both solid and hematologic malignancies. To clarify the main trends, key targets, and therapeutic indications of TCR-T therapy, this study systematically summarizes the landscape of TCR-T-targeted clinical trials based on rigorous screening of the Trialtrove database, including 260 trials before April 1, 2026. Descriptive statistics were used to analyze the trials in terms of phase, status, distribution, disease indications, primary targets, and investigational drugs. Overall, TCR-T clinical research maintains sustained enthusiasm, dominated by early-phase trials (phase I and phase I/II, accounting for 88.85%), with active trials (open and planned) accounting for 51.92% and a considerable proportion of terminated trials (21.92%). Geographically, trials are concentrated in the United States and China, which serve as core collaboration nodes, with obvious geographical clustering characteristics in regional collaboration networks. In terms of disease indications, TCR-T therapy is more focused on solid tumors, with unspecified solid tumor, non-small cell lung cancer, and head/neck cancer as the top 3 indications. NY-ESO-1 is the most prominent target, followed by MAGE-A4, KRAS, PRAME, HPV16 E6/E7, and HBV surface antigen, with letetresgene autoleucel and LioCyx-M004 being the most investigated TCR-T products. Collectively, TCR-T therapy is a promising field in tumor immunotherapy with continuous research investment and advancing clinical progress. - Source: PubMed
Publication date: 2026/05/25
Fan XingcanYu TaoLiao QiuyuSong YulinLiu Gang - Cell therapy has revolutionised the landscape of cancer treatment, with therapies such as Chimeric Antigen Receptor T cells (CAR-T cells), showing remarkable efficacy in haematological malignancies, and approaches such as Tumour Infiltrating Lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) showing increasing promise in solid tumours. The recent US FDA approvals of lifileucel (a TIL therapy for advanced melanoma) and afamitresgene autoleucel (a TCR therapy targeting MAGE-A4 in synovial sarcoma) mark the first regulatory recognition of cell therapies for solid tumours and signal a new era for oncology. Europe has played a central role in these advances, leading pivotal phase 3 trials and pioneering hospital-exemption-based manufacturing programmes. However, the continent still faces major challenges, including fragmented regulatory frameworks, high manufacturing costs, and inequitable patient access across member states. Emerging innovations such as gene-edited, allogeneic, and iPSC-derived cell products promise to address current limitations by improving scalability, safety, and time-to-treatment. This Series paper examines the latest advancements in cell therapy, focussing on the European experience, while comparing global trends. We discuss challenges specific to Europe, such as regulatory frameworks, manufacturing scalability, and disparities in access. Emphasis is placed on emerging innovations like gene-edited and allogeneic therapies, as well as future directions for integrating cell therapies into mainstream oncology. We conclude with recommendations for overcoming barriers related to cost, toxicity management, and equitable access across Europe. - Source: PubMed
Publication date: 2026/03/19
Moreno VictorThistlethwaite FionaYarza RamónTak Willemijn SLim Kok Haw JonathanHaanen John B A G - Neuroendocrine prostate cancer (NEPC) is a highly aggressive and therapy-resistant subtype of prostate cancer (PCa) that emerges following the androgen receptor (AR) targeted therapies. Identification of potential molecular drivers governing neuroendocrine differentiation (NED) and survival is critical for developing therapeutic strategies. Cancer-testis antigens of the Melanoma-associated antigen family (MAGE) are the emerging players of oncogenic regulators. However, their role in NEPC remains unexplored. - Source: PubMed
Publication date: 2026/05/05
Ramakrishna MareshaNallavolu TejaUmmanni Ramesh - The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib delays disease progression in dedifferentiated liposarcoma (DDLPS) by inducing tumor cell quiescence or senescence, though most tumors ultimately progress. Preclinical data suggest CDK4/6 inhibition enhances intratumoral inflammation and may synergize with immune checkpoint inhibitors. - Source: PubMed
Publication date: 2026/05/04
Rosenbaum EvanSeier KennethGularte-Mérida RodrigoSeffar EvanDickson Mark AAvutu ViswatejBanks Lauren BChan Jason EChi PingGounder Mrinal MKelly Ciara MKeohan Mary LMaki Robert GMovva SujanaReed DamonDesir RhoenaBiniakewitz MatthewCho Jae-MunDuchemin MicheleErinjeri Joseph PLefkowitz Robert AKoff AndrewSinger SamuelTap WilliamQin Li-XuanD'Angelo Sandra